» Articles » PMID: 22139150

Therapeutic Target-site Variability in α1-antitrypsin Characterized at High Resolution

Overview
Date 2011 Dec 6
PMID 22139150
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

The intrinsic propensity of α(1)-antitrypsin to undergo conformational transitions from its metastable native state to hyperstable forms provides a motive force for its antiprotease function. However, aberrant conformational change can also occur via an intermolecular linkage that results in polymerization. This has both loss-of-function and gain-of-function effects that lead to deficiency of the protein in human circulation, emphysema and hepatic cirrhosis. One of the most promising therapeutic strategies being developed to treat this disease targets small molecules to an allosteric site in the α(1)-antitrypsin molecule. Partial filling of this site impedes polymerization without abolishing function. Drug development can be improved by optimizing data on the structure and dynamics of this site. A new 1.8 Å resolution structure of α(1)-antitrypsin demonstrates structural variability within this site, with associated fluctuations in its upper and lower entrance grooves and ligand-binding characteristics around the innermost stable enclosed hydrophobic recess. These data will allow a broader selection of chemotypes and derivatives to be tested in silico and in vitro when screening and developing compounds to modulate conformational change to block the pathological mechanism while preserving function.

Citing Articles

Tracing genetic diversity captures the molecular basis of misfolding disease.

Zhao P, Wang C, Sun S, Wang X, Balch W Nat Commun. 2024; 15(1):3333.

PMID: 38637533 PMC: 11026414. DOI: 10.1038/s41467-024-47520-0.


Computational Tools to Assist in Analyzing Effects of the Gene Variation on Alpha-1 Antitrypsin (AAT).

Mroz J, Pelc M, Mitusinska K, Chorostowska-Wynimko J, Jezela-Stanek A Genes (Basel). 2024; 15(3).

PMID: 38540399 PMC: 10970068. DOI: 10.3390/genes15030340.


A novel pathological mutant reveals the role of torsional flexibility in the serpin breach in adoption of an aggregation-prone intermediate.

Kamuda K, Ronzoni R, Majumdar A, Guan F, Irving J, Lomas D FEBS J. 2024; 291(13):2937-2954.

PMID: 38523412 PMC: 11753496. DOI: 10.1111/febs.17121.


Probing of the reactive center loop region of alpha-1-antitrypsin by mutagenesis predicts new type-2 dysfunctional variants.

Denardo A, Ben Khlifa E, Bignotti M, Giuliani R, DAcunto E, Miranda E Cell Mol Life Sci. 2023; 81(1):6.

PMID: 38087060 PMC: 11073084. DOI: 10.1007/s00018-023-05059-1.


New variants of alpha-1-antitrypsin: structural simulations and clinical expression.

Gonzalez A, Belmonte I, Nunez A, Farago G, Barrecheguren M, Pons M Respir Res. 2022; 23(1):339.

PMID: 36496391 PMC: 9741788. DOI: 10.1186/s12931-022-02271-8.


References
1.
Halgren T . Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model. 2009; 49(2):377-89. DOI: 10.1021/ci800324m. View

2.
Tew D, Bottomley S . Probing the equilibrium denaturation of the serpin alpha(1)-antitrypsin with single tryptophan mutants; evidence for structure in the urea unfolded state. J Mol Biol. 2001; 313(5):1161-9. DOI: 10.1006/jmbi.2001.5104. View

3.
Lomas D, Evans D, Finch J, Carrell R . The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992; 357(6379):605-7. DOI: 10.1038/357605a0. View

4.
Stone S, Hofsteenge J . Kinetics of the inhibition of thrombin by hirudin. Biochemistry. 1986; 25(16):4622-8. DOI: 10.1021/bi00364a025. View

5.
Dafforn T, Mahadeva R, Elliott P, Sivasothy P, Lomas D . A kinetic mechanism for the polymerization of alpha1-antitrypsin. J Biol Chem. 1999; 274(14):9548-55. DOI: 10.1074/jbc.274.14.9548. View